Moshe Inbar

University of Haifa — Israel

Medicine · Health Sciences

33h-index12.0kcitations246works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(46), Ovarian cancer diagnosis and treatment(30), Sarcoma Diagnosis and Treatment(26), HER2/EGFR in Cancer Research(25), Breast Cancer Treatment Studies(20)

Publications245 total

The oak gall wasps of Israel (Hymenoptera, Cynipidae, Cynipini) - diversity, distribution and life history
The Catalogue of Life·2026Open Access
The oak gall wasps of Israel (Hymenoptera, Cynipidae, Cynipini) - diversity, distribution and life history
The Catalogue of Life·2026Open Access
Landslides: Forms, processes and economic significance in Israel
2026
Supplementary movies 1 - 3 from Innate ability of goats to sense and avoid ingestion of noxious insects while feeding
Open MIND·2019Open Access
Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer
Annals of Oncology·2018· 54 citedOpen Access
Phase II national clinical trial of prophylactic irradiation to the contralateral breast for BRCA mutation carriers treated for early breast cancer (EBC).
Journal of Clinical Oncology·2018· 3 cited
Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience
Targeted Oncology·2018· 11 citedOpen Access
Molecular profiling-selected treatment in metastatic gastric and oesophageal cancer: Real-life clinical experience.
Journal of Clinical Oncology·2017· 2 cited
Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome?
Colorectal Disease·2017· 3 cited
Acupuncture and Reflexology for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
Integrative Cancer Therapies·2017· 39 citedOpen Access
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial
JNCI Journal of the National Cancer Institute·2016· 28 citedOpen Access
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Annals of Oncology·2016· 39 citedOpen Access
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
The Lancet Oncology·2016· 58 cited
Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTTO trial.
Journal of Clinical Oncology·2016
Abstract P6-14-01: Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
Cancer Research·2016
Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
British Journal of Cancer·2015· 24 citedOpen Access
1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
European Journal of Cancer·2015· 3 cited
Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)
Journal of Clinical Oncology·2015· 1 cited
Abstract OT1-1-05: Phase III study of palbociclib in combination with exemestane vs. capecitabine, in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to non-steroidal aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)
Cancer Research·2015· 1 cited
Abstract PD2-4: Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
Cancer Research·2015· 5 cited
page 1 of 13Next →

Frequent Co-authors

Ofer Merimsky(14), Joseph M. Klausner(13), Mordechai Gutman(8), Samario Chaitchik(8), Isaac Meller(7), Yehuda Kollender(6), Josephine Issakov(5), Christoph Zielinski(5), Zsuzsanna Kahán(5), Tamar Safra(5), István Láng(4), Nely Wigler(4), R R Rozin(4), S. Beslija(4), Thomas Brodowicz(4), Salomon M. Stemmer(4), Dan Grisaru(4), Ravit Geva(4), Luboš Petruželka(3), Tadeusz Pieńkowski(3)